478 research outputs found
Multiplex quantitative PCR for single-reaction genetically modified (GM) plant detection and identification of false-positive GM plants linked to Cauliflower mosaic virus (CaMV) infection.
BACKGROUND:Most genetically modified (GM) plants contain a promoter, P35S, from the plant virus, Cauliflower mosaic virus (CaMV), and many have a terminator, TNOS, derived from the bacterium, Agrobacterium tumefaciens. Assays designed to detect GM plants often target the P35S and/or TNOS DNA sequences. However, because the P35S promoter is derived from CaMV, these detection assays can yield false-positives from non-GM plants infected by this naturally-occurring virus. RESULTS:Here we report the development of an assay designed to distinguish CaMV-infected plants from GM plants in a single multiplexed quantitative PCR (qPCR) reaction. Following initial testing and optimization via PCR and singleplex-to-multiplex qPCR on both plasmid and plant DNA, TaqMan qPCR probes with different fluorescence wavelengths were designed to target actin (a positive-control plant gene), P35S, P3 (a CaMV-specific gene), and TNOS. We tested the specificity of our quadruplex qPCR assay using different DNA extracts from organic watercress and both organic and GM canola, all with and without CaMV infection, and by using commercial and industrial samples. The limit of detection (LOD) of each target was determined to be 1% for actin, 0.001% for P35S, and 0.01% for both P3 and TNOS. CONCLUSIONS:This assay was able to distinguish CaMV-infected plants from GM plants in a single multiplexed qPCR reaction for all samples tested in this study, suggesting that this protocol is broadly applicable and readily transferrable to any interested parties with a qPCR platform
Infective Endarteritis in a Patient With Patent Ductus Arteriosus and Rheumatic Heart Disease
We present a 10-year old patient from Ethiopia with 3 pathologic findings: infective endarteritis with known patent ductus arteriosus and rheumatic heart disease. The patient was managed with antibiotics and ligation of the patent ductus arteriosus. She was followed up with monthly benzathine penicillin and recovered well.</p
Determinants of Adoption of Improved Crossbred Cattles: A Case Study of Suba and Laikipia Districts, Kenya
Recognizing that more than 10% of the Kenyan GDP and 50% of agricultural GDP are comprised of sales within the livestock subsector; the purpose of this research is to identify the determinants of adoption of improved crossbred cattle in rural Kenya. This research has important implications for increasing the dairy subsectors’ productivity, improving nutrient intake within rural Kenya and motivating higher rates of foreign direct investment in a sustainable, beneficial sector. We used a publicly available (www.ifpri.org) dataset called "Land Tenure, Agricultural Productivity and the Environment, 2001." A logistical regression analysis is employed to answer our research questions. The results showed that: family members education, having an extra job in addition to farming, and exposure to external market forces (was the farmer a local, or immigrant) all greatly contributed to the likelihood of adoption. This research aims to gnaw away at the ambiguity and lack of research associated with the Kenyan dairy sub-sector and aims to facilitate greater understanding and investment in the sector. Keywords: Adoption, Logistic regression, Kenya, Crossbreed cattl
Factors that transformed maize productivity in Ethiopia
Published online: 26 July 2015Maize became increasingly important in the food
security of Ethiopia following the major drought and famine
that occurred in 1984. More than 9 million smallholder house-
holds, more than for any other crop in the country, grow maize
in Ethiopia at present. Ethiopia has doubled its maize produc-
tivity and production in less than two decades. The yield,
currently estimated at >3 metric tons/ha, is the second highest
in Sub-Saharan Africa, after South Africa; yield gains for
Ethiopia grew at an annual rate of 68 kg/ha between 1990
and 2013, only second to South Africa and greater than
Mexico, China, or India. The maize area covered by improved
varieties in Ethiopia grew from 14 % in 2004 to 40 % in 2013,
and the application rate of mineral fertilizers from 16 to 34 kg/
ha during the same period. Ethiopia
’
s extension worker to
farmer ratio is 1:476, compared to 1:1000 for Kenya, 1:1603
for Malawi and 1:2500 for Tanzania. Increased use of im-
proved maize varieties and mineral fertilizers, coupled with
increased extension services and the absence of devastating
droughts are the key factors promoting the accelerated growth
in maize productivity in Ethiopia. Ethiopia took a homegrown
solutions approach to the research and development of its
maize and other commodities. The lesson from Ethiopia
’
s
experience with maize is that sustained investment in agricul-
tural research and development and policy support by the
national government are crucial for continued growth of
agricultur
Global, regional, and national burden of chronic kidney disease, 1990–2017 : a systematic analysis for the Global Burden of Disease Study 2017
Background
Health system planning requires careful assessment of chronic kidney disease (CKD) epidemiology, but data for morbidity and mortality of this disease are scarce or non-existent in many countries. We estimated the global, regional, and national burden of CKD, as well as the burden of cardiovascular disease and gout attributable to impaired kidney function, for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. We use the term CKD to refer to the morbidity and mortality that can be directly attributed to all stages of CKD, and we use the term impaired kidney function to refer to the additional risk of CKD from cardiovascular disease and gout.
Methods
The main data sources we used were published literature, vital registration systems, end-stage kidney disease registries, and household surveys. Estimates of CKD burden were produced using a Cause of Death Ensemble model and a Bayesian meta-regression analytical tool, and included incidence, prevalence, years lived with disability, mortality, years of life lost, and disability-adjusted life-years (DALYs). A comparative risk assessment approach was used to estimate the proportion of cardiovascular diseases and gout burden attributable to impaired kidney function.
Findings
Globally, in 2017, 1·2 million (95% uncertainty interval [UI] 1·2 to 1·3) people died from CKD. The global all-age mortality rate from CKD increased 41·5% (95% UI 35·2 to 46·5) between 1990 and 2017, although there was no significant change in the age-standardised mortality rate (2·8%, −1·5 to 6·3). In 2017, 697·5 million (95% UI 649·2 to 752·0) cases of all-stage CKD were recorded, for a global prevalence of 9·1% (8·5 to 9·8). The global all-age prevalence of CKD increased 29·3% (95% UI 26·4 to 32·6) since 1990, whereas the age-standardised prevalence remained stable (1·2%, −1·1 to 3·5). CKD resulted in 35·8 million (95% UI 33·7 to 38·0) DALYs in 2017, with diabetic nephropathy accounting for almost a third of DALYs. Most of the burden of CKD was concentrated in the three lowest quintiles of Socio-demographic Index (SDI). In several regions, particularly Oceania, sub-Saharan Africa, and Latin America, the burden of CKD was much higher than expected for the level of development, whereas the disease burden in western, eastern, and central sub-Saharan Africa, east Asia, south Asia, central and eastern Europe, Australasia, and western Europe was lower than expected. 1·4 million (95% UI 1·2 to 1·6) cardiovascular disease-related deaths and 25·3 million (22·2 to 28·9) cardiovascular disease DALYs were attributable to impaired kidney function.
Interpretation
Kidney disease has a major effect on global health, both as a direct cause of global morbidity and mortality and as an important risk factor for cardiovascular disease. CKD is largely preventable and treatable and deserves greater attention in global health policy decision making, particularly in locations with low and middle SDI
Global, regional, and national burden of tuberculosis, 1990–2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study
Background
Although a preventable and treatable disease, tuberculosis causes more than a million deaths each year. As countries work towards achieving the Sustainable Development Goal (SDG) target to end the tuberculosis epidemic by 2030, robust assessments of the levels and trends of the burden of tuberculosis are crucial to inform policy and programme decision making. We assessed the levels and trends in the fatal and non-fatal burden of tuberculosis by drug resistance and HIV status for 195 countries and territories from 1990 to 2016.
Methods
We analysed 15 943 site-years of vital registration data, 1710 site-years of verbal autopsy data, 764 site-years of sample-based vital registration data, and 361 site-years of mortality surveillance data to estimate mortality due to tuberculosis using the Cause of Death Ensemble model. We analysed all available data sources, including annual case notifications, prevalence surveys, population-based tuberculin surveys, and estimated tuberculosis cause-specific mortality to generate internally consistent estimates of incidence, prevalence, and mortality using DisMod-MR 2.1, a Bayesian meta-regression tool. We assessed how the burden of tuberculosis differed from the burden predicted by the Socio-demographic Index (SDI), a composite indicator of income per capita, average years of schooling, and total fertility rate.
Findings
Globally in 2016, among HIV-negative individuals, the number of incident cases of tuberculosis was 9·02 million (95% uncertainty interval [UI] 8·05–10·16) and the number of tuberculosis deaths was 1·21 million (1·16–1·27). Among HIV-positive individuals, the number of incident cases was 1·40 million (1·01–1·89) and the number of tuberculosis deaths was 0·24 million (0·16–0·31). Globally, among HIV-negative individuals the age-standardised incidence of tuberculosis decreased annually at a slower rate (–1·3% [–1·5 to −1·2]) than mortality did (–4·5% [–5·0 to −4·1]) from 2006 to 2016. Among HIV-positive individuals during the same period, the rate of change in annualised age-standardised incidence was −4·0% (–4·5 to −3·7) and mortality was −8·9% (–9·5 to −8·4). Several regions had higher rates of age-standardised incidence and mortality than expected on the basis of their SDI levels in 2016. For drug-susceptible tuberculosis, the highest observed-to-expected ratios were in southern sub-Saharan Africa (13·7 for incidence and 14·9 for mortality), and the lowest ratios were in high-income North America (0·4 for incidence) and Oceania (0·3 for mortality). For multidrug-resistant tuberculosis, eastern Europe had the highest observed-to-expected ratios (67·3 for incidence and 73·0 for mortality), and high-income North America had the lowest ratios (0·4 for incidence and 0·5 for mortality).
Interpretation
If current trends in tuberculosis incidence continue, few countries are likely to meet the SDG target to end the tuberculosis epidemic by 2030. Progress needs to be accelerated by improving the quality of and access to tuberculosis diagnosis and care, by developing new tools, scaling up interventions to prevent risk factors for tuberculosis, and integrating control programmes for tuberculosis and HIV
Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017
Background
Understanding the patterns of HIV/AIDS epidemics is crucial to tracking and monitoring the progress of prevention and control efforts in countries. We provide a comprehensive assessment of the levels and trends of HIV/AIDS incidence, prevalence, mortality, and coverage of antiretroviral therapy (ART) for 1980–2017 and forecast these estimates to 2030 for 195 countries and territories.
Methods
We determined a modelling strategy for each country on the basis of the availability and quality of data. For countries and territories with data from population-based seroprevalence surveys or antenatal care clinics, we estimated prevalence and incidence using an open-source version of the Estimation and Projection Package—a natural history model originally developed by the UNAIDS Reference Group on Estimates, Modelling, and Projections. For countries with cause-specific vital registration data, we corrected data for garbage coding (ie, deaths coded to an intermediate, immediate, or poorly defined cause) and HIV misclassification. We developed a process of cohort incidence bias adjustment to use information on survival and deaths recorded in vital registration to back-calculate HIV incidence. For countries without any representative data on HIV, we produced incidence estimates by pulling information from observed bias in the geographical region. We used a re-coded version of the Spectrum model (a cohort component model that uses rates of disease progression and HIV mortality on and off ART) to produce age-sex-specific incidence, prevalence, and mortality, and treatment coverage results for all countries, and forecast these measures to 2030 using Spectrum with inputs that were extended on the basis of past trends in treatment scale-up and new infections.
Findings
Global HIV mortality peaked in 2006 with 1·95 million deaths (95% uncertainty interval 1·87–2·04) and has since decreased to 0·95 million deaths (0·91–1·01) in 2017. New cases of HIV globally peaked in 1999 (3·16 million, 2·79–3·67) and since then have gradually decreased to 1·94 million (1·63–2·29) in 2017. These trends, along with ART scale-up, have globally resulted in increased prevalence, with 36·8 million (34·8–39·2) people living with HIV in 2017. Prevalence of HIV was highest in southern sub-Saharan Africa in 2017, and countries in the region had ART coverage ranging from 65·7% in Lesotho to 85·7% in eSwatini. Our forecasts showed that 54 countries will meet the UNAIDS target of 81% ART coverage by 2020 and 12 countries are on track to meet 90% ART coverage by 2030. Forecasted results estimate that few countries will meet the UNAIDS 2020 and 2030 mortality and incidence targets.
Interpretation
Despite progress in reducing HIV-related mortality over the past decade, slow decreases in incidence, combined with the current context of stagnated funding for related interventions, mean that many countries are not on track to reach the 2020 and 2030 global targets for reduction in incidence and mortality. With a growing population of people living with HIV, it will continue to be a major threat to public health for years to come. The pace of progress needs to be hastened by continuing to expand access to ART and increasing investments in proven HIV prevention initiatives that can be scaled up to have population-level impact
Oat-field pea intercropping for sustainable oat production: effect on yield, nutritive value and environmental impact
The aim of the study is to evaluate the effect of Oat–field pea intercropping on the yield, nutritive value, and environmental impact of oat grown under a reduced level of nitrogen fertilisation. The trial was laid out in a randomized complete block design with the following treatments: oat-0 (oat (Avena sativa L., SRCP X 80 Ab 2291 variety) without N fertilization (urea)), oat-23 (oat fertilised with 23 kg N/ha), oat-46 (oat fertilised with 46 kg N/ha), O1P1 (oat intercropped with field pea (Pisum sativum L., local variety) a ratio of 1:1), O1P2 (oat intercropped with field pea a ratio of 1:2), and O2P1 (oat intercropped with field pea at a ratio of 2:1). All of the experimental plots received standard husbandry practices except for nitrogen fertilisation. Soil pH, organic matter, total nitrogen, available phosphorus, and organic carbon were determined before and after planting. The effect of nitrogen fertilization and intercropping of oat with field pea on carbon footprint, acidification footprint, eutrophication footprint, and human toxicity footprint was calculated for each plot. Oat-0 significantly reduced the total nitrogen content of the soil, while there was no significant effect of the other treatments. O2P1 significantly out-yielded all control groups; however, it was not significantly different from fertilisation treatments. Intercropping with field pea did not significantly increase the cost of production of dry matter, crude protein, or dry matter digestibility compared to control groups. Intercropping with field pea significantly reduced the carbon footprint, acidification, eutrophication, and human toxicity footprint compared to the control groups. Therefore, oat–field pea intercrops are recommended for the production of high-quality forage at low N input with reduced environmental impact
- …
